Alife
Alife Health is a San Francisco-based AI platform for IVF clinics and patients, offering FDA-cleared embryo assessment (Embryo Predict), scheduling, outcome prediction, and patient-facing fertility tools, with enterprise deployments across US Fertility, Inception Fertility, and FutureLife.
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Alife does
Alife Health Inc. is a San Francisco-based, AI-driven fertility care platform founded in 2020 that builds software tools for in vitro fertilization (IVF) clinics and patients. The company's product portfolio spans clinical decision support (Embryo Predict for AI-based embryo assessment, Schedule Predict for clinic scheduling, Success Predictor for patient outcome forecasting, Stim Assist for medication dosing), clinic operations (Embryo Assist for embryo cataloging, Alife Assist with EMR integration), and patient-facing tools (the Alfie mobile app and a free IVF Success Calculator web tool). Its core technology applies computer vision to embryo imagery and predictive analytics to clinical and outcomes data, trained against a proprietary dataset of more than 450,000 IVF patient records.
The company's go-to-market is anchored by enterprise partnerships with three of the largest fertility networks in the United States and Europe: US Fertility (200+ physicians, 50,000+ annual IVF cycles), Inception Fertility, and FutureLife (60 clinics across 16 European countries and 77,000+ annual IVF cycles). Revenue mechanics appear to combine enterprise SaaS and per-cycle or per-assessment fees tied to clinical use of Embryo Predict, with patient-facing apps serving both as consumer acquisition funnels and ancillary engagement tools. The flagship Embryo Predict product received FDA 510(k) clearance and CE Mark certification in May 2026, with its first U.S. deployment at Reproductive Science Center (RSC) Bay Area the following month.
Alife has raised $31.5 million across a $9.5 million seed (2021) and a $22 million Series A (March 2022) led by Lux Capital, with participation from Maveron, Farvatn Venture, Union Square Ventures, Amplo, IA Ventures, and Springbank Collective. The company operates with a headcount in the 11–50 range, consistent with an early commercial-stage venture-backed profile now transitioning from regulatory milestones to scaled clinical deployment.
Alife firmographics
Firmographics- Name
- Alife
- Legal name
- Alife Health Inc.
- Website
- https://alifehealth.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alife Health is a San Francisco-based AI platform for IVF clinics and patients, offering FDA-cleared embryo assessment (Embryo Predict), scheduling, outcome prediction, and patient-facing fertility tools, with enterprise deployments across US Fertility, Inception Fertility, and FutureLife.
- Ownership category
- akta.pro rank
Alife industry classification
Industry- Product category
- Fertility Healthcare Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)
- akta.pro secondary industries
- End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), AI Observability, Monitoring & Evaluation Platforms (Drift, Quality, Safety) (HDAEANAF)
Keywords
Where Alife is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- SaaS/Software Licensing: B2B software licensing model where fertility clinics and fertility networks subscribe to access AI-powered IVF tools including Embryo Predict, Schedule Predict, Success Predictor, and Embryo Assist. Revenue likely structured as per-seat or site-based subscription given enterprise clinic targeting.
- FDA-Cleared Medical Device: Commercialization of FDA-cleared Embryo Predict tool for clinical use in U.S. fertility clinics, with CE Mark enabling Europe/U.K. commercialization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise clinic licensing - quote-based pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Alife product offering
Product offeringCore offering
Alife Health develops an AI-powered software platform for IVF and fertility care. Its offerings include Embryo Predict (an FDA-cleared AI tool for embryo assessment), Schedule Predict, Success Predictor, Embryo Assist, and Stim Assist, which clinics use to improve embryo selection, scheduling, and medication protocols. It also provides a consumer-facing Alife mobile app and a free IVF Success Calculator for patients tracking treatment journeys.
Product overview
Alife Health offers an AI-powered platform ecosystem for fertility care consisting of a core platform (Alife Assist) and multiple specialized modules. Embryo Predict is the flagship FDA-cleared AI product for embryo assessment. For clinics, the portfolio includes Embryo Assist (embryo cataloging), Schedule Predict (scheduling optimization), and Success Predictor (outcome predictions). For patients, Alife provides a mobile app for IVF journey management and a free web-based IVF Success Calculator. The platform integrates with clinic EMR systems and is designed for use by embryologists, physicians, and patients throughout the IVF process.
Differentiator
Problem solved
Functional benefit
Brands
- Embryo Predict: FDA-cleared AI-powered embryo assessment tool that analyzes blastocyst images to assist fertility specialists in embryo selection for IVF transfer decisions.
- Schedule Predict
- Success Predictor
- Alife Assist
- Alife App
Products and services
- Alife Assist Platform Configurable AI platform designed to help each member of the fertility clinic make more informed, data-based decisions, with seamless EMR integration that converts raw data into actionable insights across the IVF workflow.
- Embryo Predict FDA-cleared AI tool that analyzes Day 5, 6, and 7 blastocyst-stage embryo images to generate AI scores, providing adjunctive decision support for embryologists when selecting embryos for transfer or freezing.
- Schedule Predict AI-powered scheduling optimization tool that reduces overcapacity retrieval days by up to 65%, lowering operating costs and increasing clinic efficiency.
- Success Predictor AI-driven tool that predicts IVF success probabilities to increase patient conversion by greater than 3% and improve patient satisfaction with personalized outcome estimates.
- Embryo Assist AI software for embryology laboratories that captures embryo images and data while generating real-time activity and audit trails, enhancing embryo cataloging and standardizing embryo selection through machine learning.
- Stim Assist AI-powered tool designed to optimize medication dosages and timing for fertility treatment, helping clinicians use less medication while obtaining more mature eggs.
- Alife App Mobile application for IVF patients featuring cycle tracking, appointment and medication reminders, procedure documentation, personalized timeline, and educational content. Available on Apple App Store.
- IVF Success Calculator Free web-based tool that provides patients with a predicted chance of having a baby with IVF in the first three cycles, analyzing data from over 450,000 first cycle IVF patients to deliver personalized predictions.
Quantifiable outcome
- 72.9% clinical pregnancy rate with AI-assisted embryo selection vs 68% with traditional morphology-based grading
- +3 more outcomes
Companies that use Alife
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Alife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Alife partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, flagship and minor.
- RSC Bay AreacoreFirst clinic in the United States to deploy FDA-cleared Embryo Predict AI tool for embryo assessment in routine clinical care. Deployment enabled through existing multi-year technology partnership between RSC Bay Area's parent network US Fertility and Alife.
- FutureLife GroupflagshipNetwork-wide partnership to deploy comprehensive AI platform for fertility care across FutureLife's 60 clinics spanning 16 European countries. Includes Embryo Predict (CE-marked AI tool for blastocyst evaluation), Success Predictor, and Egg Retrieval Report tools. Following successful multi-clinic pilot. FutureLife conducts 77,000+ IVF cycles annually and is jointly owned by private equity firms CVC and Hartenberg.
- US FertilitycorePartnership to pilot Embryo Assist AI software in US Fertility's embryology laboratories. US Fertility operates more than 200 physicians across fertility centers nationwide and performs over 50,000 IVF retrieval cycles annually. Tool captures embryo images and data while generating real-time activity and audit trails.
- Inception FertilitycorePartnership to pilot AI-powered IVF tools including IVF Success Predictor and Embryo Assist software at fertility clinics across North America. Tools help patients understand treatment success probabilities and assist embryologists in standardizing embryo selection through machine learning.
- Ovation FertilitycorePartnership for AI-assisted embryo selection research and clinical implementation. Presented interim research at 80th ASRM Scientific Congress exploring AI-assisted embryo selection during IVF procedures.
- First FertilityminorClinical partner whose Chief Scientific Officer Alison Bartolucci, Ph.D., HCLD provided endorsement for Embryo Predict FDA clearance, stating the tool layers AI-driven insight onto clinical expertise.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
Alife competitors and assessment
Company assessmentDirect peers
- AIVF: AIVF is an Israel-based AI fertility company offering embryo evaluation and IVF clinic workflow software (EMMA, Life Whisperer). It is a direct competitor to Alife's Embryo Predict, pursuing the same AI-for-embryo-assessment opportunity with fertility clinics globally.
- Fairtility: Fairtility develops CHLOE, an AI-based embryo assessment and IVF decision-support platform used by clinics worldwide. It competes head-to-head with Alife's Embryo Predict in computer-vision-based embryo scoring for transfer decisions.
- Univfy: Univfy provides AI-powered IVF success prediction tools for fertility clinics and patients, directly competing with Alife's Success Predictor and IVF Success Calculator offerings.
Emerging players
- Presagen: Presagen builds AI applications across women's health and fertility, including embryo and IVF-related models, with a federated-data approach to clinical AI. It overlaps with Alife's embryo-assessment and clinic-decision-support product strategy.
Broad incumbents
- Progyny: Progyny is a leading fertility benefits management platform partnering with employers and fertility clinics. While not an AI tool itself, it controls significant patient flow into IVF clinics and represents a potential channel partner or competitor for patient-facing fertility AI.
- Kindbody: Kindbody operates a national network of fertility clinics plus employer fertility benefits. As a clinic-network incumbent expanding its own technology stack, it both overlaps with Alife's customer base and competes for technology spend.
- Carrot Fertility: Carrot Fertility is a fertility and family-forming benefits platform serving employers globally. It overlaps with Alife's patient-facing IVF tools and could either partner as a distribution channel or develop competing AI features.
- Maven Clinic: Maven Clinic is a virtual care platform for women's and family health, including fertility and preconception support. While telehealth-led, it serves the same patients and employer customers as Alife's Alife App and is a broader women's-health incumbent.
- Genea Biomedx: Genea Biomedx develops lab equipment, software, and automation for IVF clinics, including Geri time-lapse incubators. Its Geri+ platform integrates embryo imaging and analytics, competing for clinic technology budgets alongside Alife's Embryo Predict and Embryo Assist.
- Vitrolife: Vitrolife is a global IVF solutions provider offering media, lab devices, and increasingly data and AI services for fertility clinics. It is a broad incumbent whose technology stack overlaps with Alife's clinic-side product portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Alife social profiles
Digital presenceAlife compliance and trust
Trust signalCompliance4 records
Alife financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alife leadership team
Management profileNumber of profiles
Profiles1 record
Alife funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alife
What does Alife do?
Alife Health develops an AI-powered software platform for IVF and fertility care. Its offerings include Embryo Predict (an FDA-cleared AI tool for embryo assessment), Schedule Predict, Success Predictor, Embryo Assist, and Stim Assist, which clinics use to improve embryo selection, scheduling, and medication protocols. It also provides a consumer-facing Alife mobile app and a free IVF Success Calculator for patients tracking treatment journeys.
Is Alife a public or private company?
Alife is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alife founded?
Alife was founded in 2020. It employs 11 to 50 people.
Where is Alife based?
Alife is headquartered in San Francisco, United States, in the North America region.
How does Alife make money?
Two revenue lines are on record. SaaS/Software Licensing is the primary driver. The others are FDA-Cleared Medical Device.
Who are Alife's main competitors?
Direct peers on record are AIVF, Fairtility and Univfy. Presagen is listed as an emerging player. Broad incumbents are Progyny, Kindbody, Carrot Fertility, Maven Clinic, Genea Biomedx and Vitrolife.
Does Alife have an API?
No public API is recorded for Alife.
What industry is Alife in?
Alife's product category is Fertility Healthcare Software. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HDAEANAA, End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management). Its NAICS code is 5132 and its SIC code is 7372.